Literature DB >> 8386662

A new classification of germ cell tumours of the testis.

K M Grigor1.   

Abstract

The partially conflicting British and WHO classifications of testicular tumours are confusing and fail to give due prominence to their histogenesis from carcinoma in situ (CIS). Spermatocytic seminoma does not originate from CIS and should be renamed 'spermatocytoma'. All other germ cell tumours are gonocytomas arising from CIS cells which have many of the characteristics of the gonocytes of the early embryo and fetus. Gonocytomas are subdivided into seminoma, if they retain their gonocyte characteristics, or teratogenic gonocytoma if the tumour stem cell has differentiation potential. A new category of anaplastic germ cell tumour is intermediate between seminoma and teratogenic gonocytoma. The teratogenic gonocytoma is an epiblastoma if no differentiation is manifest, but may differentiate along embryonic lines into teratoma or may show extraembryonic differentiation towards yolk sac tumour or choriocarcinoma. The new classification uses unambiguous terminology and is midway between the British and WHO classifications. Those familiar with either of these classifications should have no difficulty in adapting to the new proposals, and the new classification should help others to acquire a better understanding of the biology and pathology of testicular germ cell tumours.

Entities:  

Mesh:

Year:  1993        PMID: 8386662     DOI: 10.1159/000474576

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  2 in total

1.  Heterogeneity of expression of immunohistochemical tumour markers in testicular carcinoma in situ: pathogenetic relevance.

Authors:  E Rajpert-De Meyts; M Kvist; N E Skakkebaek
Journal:  Virchows Arch       Date:  1996-06       Impact factor: 4.064

Review 2.  Etiology and early pathogenesis of malignant testicular germ cell tumors: towards possibilities for preinvasive diagnosis.

Authors:  Jenny E Elzinga-Tinke; Gert R Dohle; Leendert Hj Looijenga
Journal:  Asian J Androl       Date:  2015 May-Jun       Impact factor: 3.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.